Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ENTA 
Enanta Pharmaceuticals Inc (ENTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: ENTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.12
1 Year Target Price $19.12
| 2 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.95% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 425.00M USD | Price to earnings Ratio - | 1Y Target Price 19.12 |
Price to earnings Ratio - | 1Y Target Price 19.12 | ||
Volume (30-day avg) 6 | Beta 0.97 | 52 Weeks Range 4.09 - 15.34 | Updated Date 12/14/2025 |
52 Weeks Range 4.09 - 15.34 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-12-01 | When After Market | Estimate -1.01 | Actual -0.87 |
Profitability
Profit Margin -125.36% | Operating Margin (TTM) -121.56% |
Management Effectiveness
Return on Assets (TTM) -16.23% | Return on Equity (TTM) -84.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 294185112 | Price to Sales(TTM) 6.51 |
Enterprise Value 294185112 | Price to Sales(TTM) 6.51 | ||
Enterprise Value to Revenue 4.5 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 28852923 | Shares Floating 21856782 |
Shares Outstanding 28852923 | Shares Floating 21856782 | ||
Percent Insiders 4.9 | Percent Institutions 71.27 |
About Enanta Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2013-03-21 | President, CEO & Director Dr. Jay R. Luly Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 120 | Website https://www.enanta.com |
Full time employees 120 | Website https://www.enanta.com | ||
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.